Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Trending Stock Alerts

GERN Stock - Geron Corporation Stock Trading


home / stock / gern

GERN GERN Quote GERN Short GERN News GERN Articles GERN Message Board

MWN AI Summary *

Geron Corporation (NASDAQ: GERN) is a biopharmaceutical company focused on the development of innovative therapies for cancer treatment. Established in 1990 and headquartered in Menlo Park, California, Geron specializes in telomere biology and its implications in cancer. The company’s lead drug candidate, imetelstat, is a proprietary telomerase inhibitor designed to target cancers that are associated with telomerase activity.

Imetelstat is primarily in clinical development for hematologic malignancies, particularly myelofibrosis and acute myeloid leukemia (AML). Myelofibrosis is a rare bone marrow cancer that disrupts normal blood cell production, leading to severe anemia and an increased risk of infection. Geron has been conducting several clinical trials to assess the efficacy and safety of imetelstat in treating these conditions, garnering interest from the investment community and the healthcare sector alike.

In recent developments, Geron has reported encouraging results from its clinical trials, indicating potential as a novel treatment for patients with limited therapeutic options. The company’s focus on targeted therapies appeals to cancer treatment, where personalized medicine is gaining traction. Geron's strategic partnerships and collaborations with larger pharmaceutical companies enhance its research capabilities and market reach.

Adding to its appeal, Geron Corporation has been actively engaging with investors, weightlifting the stock price and boosting interest amidst ongoing clinical trial updates. While the market is generally volatile, Geron’s innovative approach in telomere-targeted therapies positions it uniquely in the biotech landscape.

As of late 2023, investors are tracking Geron’s progress with imetelstat closely, anticipating further developments that could significantly impact its market standing and potential revenue streams. With its commitment to advancing cancer treatments and a steady pipeline of research, Geron Corporation remains a company to watch in the biopharmaceutical space.

MWN AI Analysis *

As of October 2023, Geron Corporation (NASDAQ: GERN) continues to be a focal point in the biotech sector, drawing attention for its innovative therapies in hematologic malignancies. While the company's primary asset, imetelstat, has shown promise as a telomerase inhibitor, investors should carefully weigh the potential risks and rewards associated with its ongoing clinical trials and market dynamics.

Imetelstat's development for myelodysplastic syndromes (MDS) and essential thrombocythemia (ET) is critical, particularly as it approaches regulatory review results. Positive data could lead to significant upside, as successful approvals often drive stock price appreciation in the biotech sector. However, the inherent volatility in clinical-stage biotech stocks means that any setbacks in trial outcomes or regulatory hurdles could lead to sharp declines.

Investors should also consider the competitive landscape in hematologic malignancies, where other treatments and therapies are in active development. Geron’s market position largely hinges on the efficacy of imetelstat compared to alternatives, and the company must also navigate reimbursement landscapes and physician adoption rates post-approval.

Moreover, Geron has exhibited a careful financial strategy, securing funding through equity offerings and collaborations. The company’s cash burn rate will be a crucial factor to monitor, as it impacts the sustainability of its operations and the ability to fund ongoing and future trials without diluting shareholder value significantly.

Overall, while Geron represents a speculative investment opportunity with potential for high rewards, investors should proceed with caution. Conducting thorough due diligence, staying updated with clinical trial results, SEC filings, and market sentiment is essential. The risks inherent in the biotech sector, combined with Geron’s unique position, necessitate a balanced approach to investment, ideally positioning it within a diversified portfolio.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Geron Corporation (NASDAQ:GERN)

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug.

Quote | Geron Corporation (NASDAQ:GERN)

Last:$1.29
Change Percent: 0.0%
Open:$1.27
Close:$1.29
High:$1.33
Low:$1.25
Volume:5,222,723
Last Trade Date Time:07/17/2025 03:40:43 pm

News | Geron Corporation (NASDAQ:GERN)

  • Geron: A Tough First Year For Rytelo, But Not Yet Time To Sell (Downgrade)

    2025-06-11 11:37:57 ET Investment Overview It's been more than fifteen months since I last updated Geron Corporation ( GERN ), awarding the stock a Buy rating in March 2024. That was ahead of a crucial meeting of an FDA Advisory Committee to discuss the approval of imete...

    • June 11, 2025 11:37:57 am

    • |
    • SeekingAlpha
    • |
      • GERN Stock
      • GERN Quote
      • GERN Short
      • GERN News
      • GERN Articles
      • GERN Message Board
  • Conservative Vision Of A Positive Future For Geron

    2025-06-03 09:57:48 ET Summary This is a follow-up coverage of the Geron Corp., a small biotech company that markets first-in-class drug Imetelstat for the treatment of myelodysplastic syndrome (MDS). The first three full-quarter sales of the imetelstat did not meet stock market e...

    • June 03, 2025 09:57:48 am

    • |
    • SeekingAlpha
    • |
      • GERN Stock
      • GERN Quote
      • GERN Short
      • GERN News
      • GERN Articles
      • GERN Message Board

Message Board Posts | Geron Corporation (NASDAQ:GERN)

Subject By Source When
I can not believe these scumbags are fattening Spike5 investorshub 04/27/2023 4:21:23 PM
I think its hilarious that just the announcement Spike5 investorshub 04/25/2023 10:25:19 PM
The Inducement are here The Inducements are here!!! learningcurve2020 investorshub 04/25/2023 4:27:46 PM
whytestocks: $GERN News Article - Why Shares of Geron Are Up 30% This Week whytestocks investorshangout 04/20/2023 4:35:46 PM
Geron, CTI rally after leaked data for Legend subslover investorshub 04/19/2023 6:49:15 PM

MWN AI FAQ **

What recent developments have impacted Geron Corporation GERN's clinical trial progress and how do they influence investor sentiment?

Recent developments at Geron Corporation, including the positive results from its ongoing clinical trials for imetelstat in myelofibrosis, have bolstered investor sentiment, indicating potential market approval and increased interest in the company's future prospects.

How does Geron Corporation GERN's pipeline compare to competitors in the same therapeutic areas, and what are the implications for its market position?

Geron Corporation's pipeline, primarily focused on advanced hematologic malignancies with its lead drug imetelstat, faces strong competition but could gain a significant market position if clinical trials demonstrate superior efficacy and safety compared to competitors.

What are the financial projections for Geron Corporation GERN over the next few years, based on current research and development expenditures?

Financial projections for Geron Corporation (GERN) suggest potential revenue growth driven by advancements in its R&D pipeline, particularly in oncology, with investors cautious due to the high costs and regulatory risks associated with clinical trials over the coming years.

How does Geron Corporation GERN plan to utilize its partnerships or collaborations to enhance its drug development strategy and drive future growth?

Geron Corporation (GERN) plans to leverage its partnerships and collaborations to enhance its drug development strategy by combining resources, expertise, and innovative technologies, ultimately aiming to accelerate clinical trials and drive future growth in the hematology and oncology sectors.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get GERN Alerts

News, Short Squeeze, Breakout and More Instantly...

Geron Corporation Company Name:

GERN Stock Symbol:

NASDAQ Market:

0.0% G/L:

$1.29 Last:

5,222,723 Volume:

$1.27 Open:

$1.29 Close:

Geron Corporation Website:

Geron Corporation Logo

Ad

Trending Stock Alerts
RECENT GERN NEWS
  • GERN - Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program

    New post-hoc analyses from the IMerge trial show clinical benefit with RYTELO across patients with lower-risk myelodysplastic syndromes (LR-MDS), regardless of ring sideroblast status, baseline serum erythropoietin (sEPO) level, or prior therapy use Health-related quality-of-life (QOL) da...

  • GERN - Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 411,000 shares of its common stock, consisting of stock options to purchase an aggregate of 274,000 shares of common stock, and restricted stoc...

  • GERN - GERN Investors Have Opportunity to Join Geron Corporation Fraud Investigation with the Schall Law Firm

    The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN ) for violations of the securities laws. The investigation focu...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get GERN Alerts

Get GERN Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1